Alpha-Biased IL-2 for Stable Kidney Transplant Rejection Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Kidney transplantation faces challenges with graft failure and side effects from immunosuppressive treatments, including increased risks of infections and malignancies, necessitating improved methods to stabilize transplanted kidneys and reduce rejection.
Innovation Solution
Administering an alpha-biased IL-2 variant to kidney transplant recipients, either before or after the transplant, to enhance kidney stability and reduce rejection symptoms, potentially allowing for a taper or withdrawal of immunosuppressive agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunosuppressive treatments are administered to prevent kidney rejection, then kidney transplant stability is improved, but the risk of infections and malignancies increases
Solution Approach 1:
The patent applies local quality by using an alpha-biased IL-2 variant that selectively targets and expands regulatory T cells (Tregs) with alpha-beta integrin expression. This localized immunomodulation provides protection against kidney rejection while avoiding the broad immunosuppression that causes infections and malignancies, thus resolving the contradiction between transplant stability and harmful side effects
Solution Approach 2:
The patent employs parameter changes by modifying the IL-2 cytokine to create an alpha-biased variant with altered receptor specificity. This parameter modification shifts the immune response profile to preferentially expand Tregs rather than causing broad immunosuppression, thereby maintaining kidney transplant stability while reducing the risk of infections and malignancies
2Duration of action of stationary object
If immunosuppressive agents are used to prevent rejection, then kidney transplant stability is improved, but long-term side effects worsen
Solution Approach 1:
The patent converts the harmful effect of broad immunosuppression into a beneficial targeted approach by using alpha-biased IL-2 to selectively expand regulatory T cells. This transforms the strategy from suppressing the entire immune system (which causes harmful side effects) to specifically enhancing the regulatory component that prevents rejection, thereby maintaining long-term kidney stability while eliminating harmful side effects
3Reliability
If standard immunosuppressive therapy is administered, then rejection is prevented, but the complexity of treatment increases
Solution Approach 1:
The patent extracts the essential protective function from complex immunosuppressive regimens by isolating and enhancing the regulatory T cell pathway through alpha-biased IL-2. This extraction approach maintains rejection prevention while simplifying treatment by replacing or reducing the need for multiple immunosuppressive agents with a single targeted therapy
Data Source
AI summary
The present invention provides, among other things, a method of prophylaxis for kidney rejection comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplant. In another aspect, the present invention provides, among other things, a method of improving a kidney transplant in a recipient, comprising administering to the recipient an alpha-biased IL-2 variant in conjunction with the kidney transplantation at a therapeutically effective amount, wherein the improvement in the kidney transplant results in prolonged stability of the kidney transplant, survival of the recipient, and/or reduced rejection symptoms as compared to a control.